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(57) ABSTRACT 
The post-translational addition of a farnesyl moiety to the 
Ras oncoprotein is essential for its membrane localization 
and is required for both its biological activity and ability to 
induce malignant transformation. The present invention 
describes design and synthesis of a farnesylpyrophosphate 
(FPP) analog, 8-anilinogeranyl pyrophosphate (AGPP) that 
is transferred to Ras by farnesyltransferase (FTase), in Which 
the (Jo-terminal isoprene unit of the farnesyl group has been 
replaced With an aniline functionality. AGPP potently inhib 
ited FTase activity in vitro (IC5O=0.6 pM) and is highly 
selective shoWing little inhibitory activity against either 
geranylgeranyl-protein transferase type I (GGTase I) (IC5O= 
31 pM) or the utilization of FPP by the enzyme squalene 
synthase (IC50=1000 ttM). Kinetic analyses suggest that 
AGPP acts as a competitive inhibitor of FTase With respect 
to FPP. In vitro studies using [3H]AGPP shoW that the 
analog Was appropriately transferred by FTase to Ras. Deriv 
itization of AGPP With a bulky iodo group on the aniline ring 
does not signi?cantly alter its biochemical properties. These 
data indicate that the modi?ed molecules are the ?rst truly 
transferable analogs of FPP and open the door to additional 
analogs to probe the biological function of protein farnesy 
lation. 
17 Claims, 10 Drawing Sheets 
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FARNESYL PYROPHOSPHATE ANALOGS 
This application claims priority from provisional appli 
cation 60/112,208, ?led on Dec. 15, 1998. 
FIELD OF THE INVENTION 
The present invention relates to farnesyl pyrophosphate 
analogs and their use in modulating cellular chemistry. More 
speci?cally, the invention relates to unsubstituted and sub 
stituted anilinogeranyl pyrophosphates (AGPP), unsubsti 
tuted and substituted benZyloXyalkylisoprenyl 
pyrophosphates, the processes of making the same, inter 
mediates for use in the process of making the same, and the 
methods of using the EFF analogs in substitution for farnesyl 
pyrophosphate (FPP) or as farnesyl transferase inhibitors 
(FTIs). 
BACKGROUND OF THE INVENTION 
Farnesyl pyrophosphate 1 (FPP) and its C2O homolog, 
geranylgeranyl pyrophosphate (GGPP) are isoprenoids that 
are involved in a number of cellular processes including 
cholesterol biosynthesis, glycoprotein biosynthesis, vitamin 
and cofactor synthesis and protein prenylation. Recently, the 
enZyme farnesyltransferase (FTase) Which can utiliZe FPP or 
GGPP as a substrate depending on the nature of the [3 
subunit, has attracted considerable interest as a possible 
target for the design of chemotherapeutic agents. 
An area of interest is the continued search for proteins that 
are post-translationally modi?ed in cells as part of normal 
metabolism. Farnesylation has been shoWn to be required 
for the normal function of various proteins including Ras. 
Mutated forms of the cellular Ras genes are among the 
most common genetic abnormalities in human cancer, 
occurring in 30% of all neoplasms. This frequency indicates 
an important role for aberrant Ras function in carcinogenesis 
(1). Ras proteins are synthesiZed as cytosolic precursors 
Which localiZe to the inner lea?et of the plasma membrane 
only after undergoing a series of Well de?ned posttransla 
tional modi?cations The ?rst and obligatory step in this 
processing is the transfer by protein farnesyltransferase 
(FTase) of the 15-carbon isoprene farnesyl from farnesylpy 
rophosphate (FPP) to a cysteine residue located at the Ras 
C-terminus via a thioether linkage (2,3). This Cys residue 
forms part of the prenylation recognition sequence, CAAX 
(Where Ais an aliphatic residue and X is most often Met, Ser, 
or Gln), present in all Ras proteins Prenylation is 
folloWed by proteolytic removal of the COOH-terminal 
tripeptide and carboXymethylation of the noW terminal, 
prenylated cysteine These modi?cations render the 
C-terminus hydrophobic, Which is thought to promote the 
association of these proteins With the plasma membrane. 
Studies employing site-directed mutants Within the Ras 
CAAX motif (5,6) or inhibitors of 3-hydroXyl-3 
methylglutaryl CoA reductase (7), the rate limiting enZyme 
in isoprenoid biosynthesis, have demonstrated that isopre 
nylation is required for Ras proteins to become membrane 
associated and to induce cellular transformation. 
Three distinct enZymes responsible for protein isopreny 
lation have been isolated and biochemically characteriZed 
(2). In addition to FTase, tWo geranylgeranyl-transferases 
(GGTases) have been isolated and have been shoWn to 
modify speci?c protein substrates. While the CAAX 
GGTase (also knoWn as GGTase-1) geranylgeranylates pro 
teins Which end in a CAAL sequence, Where C is cysteine, 
A is usually an aliphatic amino acid, and L is leucine (8,9), 
the Rab GGTase (also knoWn as GGTase-2) catalyZes the 
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attachment of tWo geranylgeranyl groups to paired carboXyl 
terminal cysteines in members of the Rab family of GTP 
binding proteins (10). These proteins terminate in a CC or 
CXC motif. 
A number of basic issues pertaining to the biological 
function of protein isoprenylation, and the contribution of 
lipid modi?cation in general, remain to be ansWered. While 
farnesylation of Ras is absolutely required for its biological 
effects and membrane localiZation, it is unknoWn Whether 
the prenyl group functions as a hydrophobic membrane 
association signal (11—16) or by targeted protein-protein 
recognition (17,18). The functional signi?cance of protein 
farnesylation versus geranylgeranylation to the biological 
activity of prenylated proteins is also unknoWn. Studies 
employing inhibitors of FTase have highlighted the impor 
tance of isoprenylation to the membrane association and 
activity of the Ras family of signal transduction proteins. 
HoWever, inhibition of protein prenylation precludes relat 
ing the effects of many of the doWnstream events such as 
further modi?cation of the target protein by palmitoylation, 
proteolysis and carboXymethylation to the biological func 
tion of Ras. 
EXtensive research studies have established an important 
contribution of aberrant Ras function to human carcinogen 
esis (88, 89) Consequently, there is considerable interest in 
the development of inhibitors of Ras function for use in 
cancer treatment. Since Ras function is absolutely dependent 
on lipid modi?cation and tight association With the plasma 
membrane, the development of drugs that block Ras mem 
brane association has attracted the greatest interest (89—91). 
FTase has proven to be a biochemical target for the devel 
opment of inhibitors of post-translational processing of Ras 
that act as potent anti-Ras drugs. 
Several general approaches have been employed in the 
identi?cation and development of speci?c FTase inhibitors 
(revieWed in 88). First, high throughput random screens 
have been used to identify natural or library compounds that 
inhibit the ability of FTase to catalyZe the addition of 
farnesyl to recombinant Ras in vitro. Second, Ras CaaX 
tetrapeptide sequences alone are suf?cient to signal modi 
?cation by farnesylation and can serve as potent inhibitors of 
FTase activity in vitro. Therefore, a variety of CaaX-based 
peptidomimetic compounds have been synthesiZed. 
Consequently, the potent and selective FTIs identi?ed to 
date include a diverse collection of structurally unrelated 
compounds. HoWever, the structural requirements of the 
prenyl group have not been uncovered. 
The initial characteriZation of FTIs Was done in ?broblast 
model systems transformed by oncogenic H-Ras (92, 93). 
These studies clearly shoWed that FTIs can potently and 
speci?cally inhibit H-Ras farnesylation, Without affecting 
the modi?cation of geranylgeranylated proteins. FTI inhi 
bition of H-Ras processing correlated directly With inhibi 
tion of H-Ras-induced signaling, morphologic and groWth 
transformation (94). Similar dramatic results Were seen in in 
vivo tumor models using Ras-transformed rodent cells 
groWn as Xenografted tumors in nude mice (95), and in viral 
H-Ras transgenic mice in Which salivary and mammary 
tumors occur stochastically in a high percentage of mice 
carrying the transgene (96, 97). An unexpected, but desired, 
aspect of these studies is the apparent lack of normal cell 
toXicity. This Was uneXpected because farnesylation is 
required for normal Ras function, Which is critical for 
normal cell viability (97). The reason(s) for the relative 
resistance of normal cells to FTIs is presently not knoWn. 
Because of previous ?nding that FTIs Were capable of 
inhibiting Ras transformation in animal model systems, and 
US 6,284,910 B1 
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because of the Widespread tendency to vieW FTIs as Ras 
inhibitors rather than FTase inhibitors, many investigators 
assumed that human tumors cells that contained mutated Ras 
proteins Would be more sensitive to FTI action than those 
that did not. HoWever, studies have shoWn that ras mutation 
status is not predictive of FTI sensitivity (98). Indeed, it is 
clear that these drugs interfere With the processing of other 
farnesylated proteins in addition to Ras. There is noW 
evidence that FTIs may block Ras transformation, in part, by 
inhibiting the function of other farnesylated proteins, one or 
more of Which may represent the critical target for FTI 
action (87, 99, 100). 
It is clear that the cellular mechanism by Which FTIs eXert 
their biological activity is incompletely understood (88). 
TWo central issues appear that must be addressed before the 
biochemical mechanism by Which FTIs function can be 
understood. First, it is necessary to understand the biological 
signi?cance of the isoprenoid lipid in the conteXt of the 
function of a fully processed prenyl protein. For FTIs, the 
natural targets for this analysis are the Ras oncoproteins. 
Second, as outlined above, it is likely that FTIs inhibit the 
farnesylation of additional cellular proteins, many of Which 
remain to be identi?ed, and are likely to depend upon 
prenylation for some aspect of their function. Therefore, the 
key to applying FTase-based pharmacological intervention 
is a thorough understanding of the in vivo farnesylation 
pathWays. Knowledge of the complete array of cellular 
protein substrates and substrate speci?cities for FTase and 
the cellular role of the isoprenoid moiety Will be critical in 
improving the design and action of effective FTIs. 
Prenyl analogs and FTIs have contributed to the under 
standing of prenylation and such information is useful in the 
design and evaluation of therapeutics. The mechanism 
underlying FTI action is of interest for several reasons. The 
action of the drug is likely to be secondary to the speci?c 
inhibition of Ras farnesylation, suggesting that additional 
farnesylated proteins yet to be identi?ed or assigned a 
cellular function play a critical role in the biology of 
transformation (90). Second, several FTIs are currently 
entering phase I trials as anticancer drugs in humans and 
rational clinical development Will depend on understanding 
the biochemical basis for their inhibition of cell groWth. 
SUMMARY OF THE INVENTION 
The present invention provides for the preparation and 
functional characteriZation of unsubstituted anilinogeranyl 
pyrophosphate (AGPP), substituted anilinogeranyl 
pyrophosphate, unsubstituted and substituted benZyloXy 
alkylisoprenyl pyrophosphate, and pharmaceutically accept 
able salts thereof, Which meet the criteria set forth for FPP 
analogs (i.e. FTase substrates and inhibitors) in the Back 
ground of the Invention. AGPP and other FPP analogs of the 
invention are recogniZed and transferred to Ras by FTase 
With in vitro kinetic properties that are indistinguishable 
from those of FPP. AGPP can be modi?ed by iodination 
Without signi?cantly altering these properties, alloWing syn 
thesis of additional analogs. Other analogs of FPP Wherein 
the uu-isoprenyl moiety is replaced by either a functionaliZed 
aniline or a functionaliZed benZyloXy group may be synthe 
siZed by alternate routes. Finally, the present invention 
reveals that AGPP and other FPP analogs of the invention 
are poorly recogniZed by, and transferred to, substrate by 
GGTase I and are neither substrates for, nor inhibitors of, 
squalene synthase, suggesting a high degree of selectivity 
toWard FTase in vivo. Thus, the present invention provides 
for a method of using AGPP as a substrate for FTase in the 
prenylation of Ras. 
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It is accordingly an aspect of the invention to provide a 
FPP analogs Which Would be ef?ciently utiliZed by FTase, 
alloW for further derivatiZation for high speci?c activity 
labeling or cross linkers to be designed, and that Would be 
recogniZed and transferred to FTase substrate proteins With 
an activity approaching that of FPP. Such FPP mimetic 
molecules can interfere With other cellular events, While 
acting as non FTI anti-Ras molecules. 
FPP analogs of the invention also inhibit the function of 
FTase. 
It is accordingly another aspect of the invention to provide 
FPP analogs that are inhibitors of farnesyl transferase and 
therefore affect intracellular processes involving the transfer 
of farnesyl to intracellular proteins essential to the function 
ing of those intracellular proteins. 
Conceptually, FPP can be vieWed as a four-section mol 
ecule. The ot-isoprene and the pyrophosphate moiety remain 
invariant in all of the FPP analogs of the present invention 
because an allylic pyrophosphate is essential for FTase 
catalyZed transfer to protein substrate (117). 
The structure of FPP: 
)\/\\)\/\\)\/\\OPP 
(Jo-isoprene [5-isoprene ot-isoprene Pyrophosphate, 
Aniline Isoprene Invariant 
OT OBZ or Alkylene Isoprene 
The captions beloW the ot-, [3-, and uu-isoprene units of 
FPP above represent the general substitutions made for the 
isoprene unit in compounds according to the invention, 
Wherein aniline may be unsubstituted or substituted, OBZ is 
a benZyloXy group, Which is unsubstituted or substituted as 
indicated in Formulae I-II beloW, and alkylene is an alkylene 
linking group having 1 to 10 carbon atoms. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Structure of farnesylpyrophosphate 1, gera 
nylgeranylpyrophosphate 2, 8-anilinogeranyl pyrophos 
phate (AGPP) 3a, p-iodo-8-anilinogeranyl pyrophosphate 
(AGPP) 3b. 
FIG. 2. Differential Inhibition of Farnesyltransferase and 
CAAX Geranylgeranyltransferase by AGPP. The assay miX 
tures contained (in a ?nal volume of 25 pl) various compo 
nents as described in “Experimental Procedures”. After 
incubation for 15 min at 37° C., the amount of [3H]prenyl 
group transferred to the appropriate protein substrate [H-Ras 
(CVLS) for FTase and H-Ras (CVLL) for CAAX GGTase] 
Was measured by precipitation With ethanol-HCl. The assays 
contained 10 ng recombinant rat FTase, 5 pM H-Ras, and 0.6 
pM [3H]FPP (33,000 dpm/pmol) or 100 ng recombinant rat 
CAAX GGTase, 5 pM H-Ras CVLL, and 1 pM [3H]GGPP 
(33,000 dpm/pmol) and the indicated concentration of unla 
beled AGPP. The 100% of control values Were 1.1 and 5.5 
pmol of [3H]farnesyl or [3H]geranylgeranyl transferred per 
tube. Each value is the average of duplicate incubations and 
is representative of tWo separate experiments. 
FIG. 3. Inhibition of Farnesyltransferase by AGPP and 
I-AGPP. The enZymatic activity Was measured in the pres 
ence of the various concentrations of either AGPP or 
I-AGPP as described in FIG. 3. The 100% control values 
US 6,284,910 B1 
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Were 1.9 and 2 pmol. Each value is the average of duplicate 
incubations and is representative of three separate experi 
ments. 
FIG. 4. Transfer of Anilinogeranyl from [3H]AGPP to 
p21HH'mS by Farnesyltransferase. (A) Each reaction con 
tained 1 pM [3H]AGPP (37,400 dpm/pmol) and 10 ng of 
recombinant FTase in the absence (triangles) or presence 
(circles) of 5 pM p2lHa'ms Duplicate samples Were incu 
bated for the indicated times at 37° C., and ethanol-HCl 
precipitated radioactivity Was measures as described under 
“Experimental Procedures”. The inset shoWs the migration 
of on a 12.5% SDS-polyacrylamide gel of an aliquot from 
the reaction carried out for 1 hr in the presence (+) or 
absence (—) of p2lHa'ms. The gel Was treated With Amplify 
solution (Amersham), dried, and exposed to Kodak 
X-OMAT AR ?lm for 2 days at —70° C. The migration of 
molecular Weight markers placed in a adjacent lane is 
shoWn. (B) The AGPP substrate saturation curve for FTase 
Was determined by varying the amount of [3H]AGPP in the 
standard reaction described above. Assays Were carried out 
in duplicate for 30 min at 37° C., and the ethanol-HCl 
precipitable radioactivity measured. The data is representa 
tive of three independent experiments. 
FIG. 5. [3H]AGPP and [3H]FPP are Bound and Trans 
ferred With Comparable Af?nities by Farnesyltransferase. 
Farnesyltransferase (10 ng) Was incubated in a ?nal volume 
of 25 pl in the presence of 1.0 pM [3H]AGPP or [3H]FPP and 
5 pM Wild-type p21HH'mS. After incubation for 30 min at 37° 
C., the amount of [3H]prenyl transferred to p2lHa'ms Was 
determined as described under “Experimental Procedures”. 
Each value is the average of duplicate incubations and is 
representative of ?ve separate experiments. 
FIG. 6. Identi?cation of [3H]AGPP-Derived Radioactive 
Material Transferred to p2lHa'ms. An aliquot from a stan 
dard FTase reaction Was subjected to Pronase E digestion as 
described under “Experimental Procedures”. The labeled 
products, extracted With 1-butanol, Were analyZed on C18 
reverse-phase TLC plates developed in acetonitrile:Water 
:acetic acid (75:25 :1). Radioactive Zones Were located With 
a Bioscan Imaging System 200-IBM. The arroWs indicate 
the position of authentic F-Cys, GG-Cys, and AG-Cys. O 
and F denote the positions of the origin and solvent front. 
The data shoWn are representative of tWo independent 
experiments. 
FIG. 7. Inhibition of Squalene Synthase by AGPP. The 
initial rates of squalene synthase activity Were determined 
from bovine brain microsomal preparations in the presence 
of the indicated concentration of unlabeled AGPP (?lled 
squares) or unlabeled FPP (open triangles) under the in vitro 
conditions described in “Experimental Procedures.” Crude 
bovine brain microsomes and 0.05 mM [3H]FPP (105 cpm/ 
pmol) and unlabeled AGPP and FPP Were added at the 
indicated concentrations and incubated for 30 min. at 37° C. 
The reactions Were terminated With 40% (Wt/vol) KOH and 
95% ethanol. Authentic carrier squalene (20 pg) Was added 
and the reactions extracted With petroleum ether. The 
amount of labeled lipid formed Was measured by scintilla 
tion counting. Each value is the average of duplicate incu 
bations and is representative of three separate experiments. 
FIG. 8. Progress Curves for Transfer of FPP and Analog 
Pyrophosphates to Dansyl-GCVLS by FTase. The reaction is 
monitored for ?uorescence intensity at 505 nm With exci 
tation at 340 nm. (a) FPP, (b) AGPP, (c) 
8-(penta?uoroaniline)geranyl pyrophosphate, (d) blank. 
FIG. 9. AGPP Rescues the Biological Activity of Onco 
genic H-Ras in Isoprenoid Depleted Oocytes With Delayed 
Maturation Kinetics Relative to FPP. 
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DETAILED DESCRIPTION OF THE 
INVENTION 
The farnesyl pyrophosphate analogs of this invention are 
useful as substrates for FTase, and in particular for FTase 
mediated isoprenylation of proteins such as the Ras protein. 
The farnesyl pyrophosphate analogs of the invention are 
also useful as farnesyl transferase inhibitors (FTIs). 
The farnesyl pyrophosphate analogs of this invention may 
be prepared in free base form, or they may be prepared in the 
form of pharmaceutically acceptable salts according to the 
conventional practice in the pharmaceutical arts. Likewise, 
they can be prepared in pharmaceutically acceptable form in 
combination With carriers, adjuvants, excipients and the like. 
The dosages of the compounds, their pharmaceutically 
acceptable salts and compositions containing them may be 
determined by conventional clinical methods in the art. 
The farnesyl pyrophosphate analogs according to this 
invention may be employed for the treatment of human and 
non-human patients in Which modulation of farnesyl pyro 
phosphate or FTase inhibition is desired. As farnesyl pyro 
phosphate is involved in a number of cellular processes 
including cholesterol biosynthesis, glycoprotein 
biosynthesis, vitamin and cofactor synthesis and protein 
prenylation, the compounds of the present invention are 
useful for affecting such cellular processes and disease states 
caused thereby. Also, as FTase is involved in farnesylation 
of important intracellular proteins such as Ras, the com 
pounds of the present invention are useful for treating 
disease states in Which farnesylation of important intracel 
lular proteins such as Ras is implicated, such as cancer. 
Recently, the enZyme farnesyltransferase (FTase) Which 
can utiliZe FPP or GGPP as a substrate, depending on the 
nature of the [3 subunit, has attracted considerable interest as 
a possible target for the design of chemotherapeutic agents. 
The present invention thus contemplates a method of treat 
ing conditions that are affected by FPP and its analogs. 
The compounds of this invention are illustrated by general 
Wherein the phenyl ring is unsubstituted or substituted. 
Suitable substituents for the phenyl ring are, for example, H, 
halo, NO2, NH2, NHR7, N(R7)2, N(R7)3+, N3, OH, OR7 and 
optionally substituted C1 to C8 alkyl. R7 is CM—C8 alkyl (e.g. 
methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl, s-butyl, 
t-butyl, n-pentyl, etc.) or C1—C8 alkanoyl (e.g. formyl, 
acetyl, propanoyl, etc.). G4 is OPP, OR8, or S-linked cys 
teine (Which may be in the R, S or racemic con?guration). 
And R8 is a suitable hydroxy protecting group. 
(1) 
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n is an integer of 0 to 14, inclusive; 
R6 is H or alkyl. 
Throughout this description, OPP is the pyrophosphate 
group: 
O O 
|| II 
In general, according to the present invention, alkyl is a 
C1 to C8 alkyl substituent group. Examples of alkyl are 
methyl, ethyl, i-propyl, n-propyl, n-butyl, t-butyl, s-butyl, 
i-butyl, pentyl, etc. Suitable optional substitutents for such 
alkyl groups may be one or more substituents such as amine, 
alkyl amine, dialkylamine, nitrile, and hydroxy. Preferred 
substituted alkyl groups are hydroxymethyl, hydroxyethyl, 
aminomethyl, aminoethyl, (NC)CH2—, and (NC) 
CH2CH2—. 
A preferred embodiment of the above compounds of 
formula I is illustrated by formula II: 
<11) 
R1 
R4 
Wherein R1, R2, R3, R4, and R5 are, for example, H, halo, 
NO2, NH2, NHR7, N(R7)2, N(R7)3+, N3, OH, OR7, C1 to C8 
alkyl, amino C1—C8 alkyl, hydroxy C1—C8 alkyl, nitrile 
C1—C8 alkyl, etc. G1, G2, G3, and G4 are de?ned in formula 
I. The variable m is an integer of 0 to 5. R7 is C1—C8 alkyl 
(e.g. methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl, 
s-butyl, t-butyl, n-pentyl, etc.) or C1—C8 alkanoyl (e.g. 
formyl, acetyl, propanoyl, etc.) etc. 
Another preferred embodiment of compounds of formula 
I is illustrated by formula III: 
(III) 
R1 IIKG 
R2 NM \ \ OPP 
R3 
Wherein R1, R2, R3, R4, and R5 are, for example, H, halo, 
NO2, NH2, NHR7, N(R7)2, N(R7)3+, N3, OH, OR7, C1—C8 
alkyl, amino C1—C8 alkyl, hydroxy C1—C8 alkyl, nitrile 
C1—C8 alkyl, etc. R7 is C1—C8 alkyl (e.g. methyl, ethyl, 
i-propyl, n-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, 
etc.) or C1—C8 alkanyl (e.g. formyl, acetyl, propanoyl, etc.) 
etc., and alkyl is C1 to C8 alkyl, for example methyl, ethyl, 
n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, 
etc. 
An even more preferred embodiment of compounds of 
formula III is represented by formula IV: 
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R1 R2 N 
\ \ OPP 
R3 
Wherein 
R1, R2, R4, and R5 are H or F; 
R3 is H, NO2, I, F or N3; and 
R6 is H, methyl or ethyl. 
Another preferred compound of formula I is represented 
by formula 11: 
R1 I|K6 
R. Owed 
11 
COO 
R3 R5 
Wherein R1—R6 are de?ned above in formula I and the 
moiety: 
COO 
is the aforementioned S-linked cysteine, Which may be in the 
R, S or racemic con?guration, more preferably in the 
S-con?guration (i.e. derived from the naturally occurring 
cysteine). 
Preferred compounds of formula 11 are those in Which, 
R1—R6 are H and the S-linked cysteine is in the 
S-con?guration (compound 11a). 
Even more particularly preferred compounds of formula 
IV include: 
(1) 8-aniline-3,7-dimethyl-2,6-octadiene pyrophosphate 
(AGPP); 
(2) 8-(4-nitroaniline)-3,7-dimethyl-2,6-octadiene pyrophos 
phate; 
(3) 8-(4-iodoaniline)-3,7-dimethyl-2,6-octadiene pyrophos 
phate; 
(4) 8-penta?uoroaniline-3,7-dimethyl-2,6-octadiene pyro 
phosphate; 
(5) 8-(4-aZido-2,3,5,6-tetra?uoroaniline)-3,7-dimethyl-2,6 
octadiene pyrophosphate; and 
(6) 8-(N-ethyl-4-aZido-2,3,5,6-tetra?uoroaniline)-3,7 
dimethyl-2,6-octadiene pyrophosphate. 
Another preferred embodiment of the compounds of 
formula I is exempli?ed by the compounds of formula V: 
US 6,284,910 B1 
(V) 
R4 
R3 R5 
0 R2 Wow 
R1 
wherein R1—R5 are as de?ned in formula I, p is an integer 
from 1 to 10 and OPP stands for the pyrophosphate group. 
Particularly preferred compounds of formula V are eXem 
pli?ed by formula VI: Wherein R1—R5 are as in formula V, 
above; q is an integer of 1 to 5, inclusive; and OPP is the 
R4 
R3 R5 
0 R2 WOPP 
R1 
pyrophosphate group. 
Particularly preferred compounds of formula VI include 
compounds exempli?ed by formula VII: 
R4 
R3 R5 
0 R2 Mow 
R1 
Wherein R3 is as de?ned in formula VI other than H; and R1, 
R2, R4, and R5 are as de?ned in formula VI; r is an integer 
of 1 to 5, inclusive; and OPP is the pyrophosphate group. 
Particularly preferred compounds of formula V have been 
synthesiZed, including: 
(VI) 
(VII) 
6-benZyloXy-3-methyl-2-heXene pyrophosphate (12); 
7-benZyloXy-3-methyl-2-heptene pyrophosphate (13); 
8-benZyloXy-3-methyl-2-octene pyrophosphate (14); 
9-benZyloXy-3-methyl-2-nonene pyrophosphate; and 
10-benZyloXy-3-methyl-2-decene pyrophosphate. 
Another preferred embodiment of compounds of formula 
I is exempli?ed by the compounds of formula VIII: 
(VIII) 
R1 
R2 0 O/\/{ WON, 
R3 R5 
R4 
Wherein R1—R5 are as de?ned in formula I, preferably NO2, 
N3, NH3, halo, such as F, Cl, Br and I, 1—8 carbon alkyl such 
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as methyl, ethyl, i-propyl, n-propyl, i-butyl, n-butyl, s-butyl, 
t-butyl, etc. The variable s is an integer from 1 to 5. 
Another preferred embodiment of compounds of formula 
II includes the compounds of formula IX: 
(IX) 
R6 ILMOVWOPP 
R5 
Wherein R1—R5 are is as de?ned in formula I, t is an integer 
from 1 to 5 and R6 is hydrogen or C1—C8 alkyl. 
Another preferred embodiment of compounds of formula 
I includes compounds of formula X: 
(X) 
R4 
R3 R5 
R2 N I WON 
R1 R6 
Wherein R1—R6 are as de?ned in formula I, above and u is 
an integer number 1 to 10. 
Another aspect of the invention relates to a novel oligo 
ether of formula XI: 
HOMOVWOPP 
Wherein v is an integer from 1 to 10, inclusive; and OPP is 
the pyrophosphate group. 
Another aspect of the invention relates to compounds of 
the formula XII: 
HO WON) W 
Wherein W is an integer of 1 to 10, inclusive and OPP is the 
pyrophosphate group. 
Another aspect of the claimed invention relates to allylic 
diols of formula XIII: 
Wherein Z is an integer of 1 to 14. 
Compounds of formula I possess a pyrophosphate group 
Which is acidic under physiologic conditions. The com 
(XI) 
(XII) 
(XIII) 
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pounds of the invention may therefore be formulated in the 
form of free acid. They may also be formulated as pharma 
ceutically acceptable salts by conventional methods Well 
knoWn in the art, such as by combining an acidic compound 
of the present invention With a physiologically tolerated 
base. Such bases include alkali or alkaline earth metal 
hydroxides such as NaOH, KOH, LiOH, etc. Such bases also 
included organic amines such as dibenZylethylenediamine, 
trimethylamine, piperidine, pyrrolidine, benZylamine and 
the like, or a quaternary ammonium hydroxide such as 
tetramethylammonium hydroxide, and the like. 
The compounds and pharmaceutically acceptable salts of 
the invention may be combined With pharmaceutically 
acceptable carriers, excipients, adjuvants, and the like, to 
form pharmaceutical compositions. The pharmaceutical 
compositions may comprise other physiologically tolerated 
and/or bene?cial compounds. Suitable carriers may be solid, 
such as binders and cutting agents conventional in the pill, 
tablet and capsule forming arts, or liquid, such as solvents, 
diluents and emulsi?ers conventional in the parenteral and 
oral elixir compounding arts. 
Pharmaceutical compositions comprising compounds of 
the invention or pharmaceutically acceptable salts thereof 
advantageously contain 0.01% to 100% by Weight of the 
compound or a pharmaceutically acceptable salt of the 
invention, preferably 0.1% to 50%, and even more prefer 
ably 1 to 25%. 
The compounds of this invention inhibit farnesyl-protein 
transferase and the farnesylation of the oncogene protein 
Ras. These compounds are useful as pharmaceutical agents 
for mammals, especially for humans. These compounds may 
be administered to patients for use in the treatment of cancer. 
Examples of the type of cancer Which may be treated With 
the compounds of this invention include, but are not limited 
to, colorectal carcinoma, exocrine pancreatic carcinoma, and 
myeloid leukemias. 
The compounds of this invention may be administered to 
mammals, preferably humans, either alone or, preferably, in 
combination With pharmaccutically-acceptable carriers or 
diluents, optionally With knoWn adjuvants, such as alum, in 
a pharmaceutical composition, according to standard phar 
maceutical practice. The compounds can be administered 
orally or parenterally, including intravenous, intramuscular, 
intraperitoneal, subcutaneous and topical administration. 
For oral use of a chemotherapeutic compound according 
to this invention, the selected compounds may be 
administered, for example, in the form of tablets or capsules, 
or as an aqueous solution or suspension. In the case of tablets 
for oral use, carriers Which are commonly used include 
lactose and corn starch, and lubricating agents, such as 
magnesium stearate, are commonly added. For oral admin 
istration in capsule form, useful diluents include lactose and 
dried corn starch. When aqueous suspensions are required 
for oral use, the active ingredient is combined With emul 
sifying and suspending agents. If desired, certain sWeetening 
and/or ?avoring agents may be added. For intramuscular, 
intraperitoneal, subcutaneous and intravenous use, sterile 
solutions of the active ingredient are usually prepared, and 
the pH of the solutions should be suitably adjusted and 
buffered. For intravenous use, the total concentration of 
solutes should be controlled in order to render the prepara 
tion isotonic. 
The present invention also encompasses a pharmaceutical 
composition useful in the treatment of cancer, comprising 
the administration of a therapeutically effective amount of 
the compounds of this invention, With or Without pharma 
ceutically acceptable carriers or diluents. Suitable compo 
12 
sitions of this invention include aqueous solutions compris 
ing compounds of this invention and pharmacologically 
acceptable carriers, e.g., saline, at a pH level, e.g., 7.4. The 
solutions may be introduced into a patient’s intramuscular 
5 blood-stream by local bolus injection. 
When a compound according to this invention is admin 
istered into a human subject, the daily dosage Will normally 
be determined by the prescribing physician With the dosage 
generally varying according to the age, Weight, and response 
of the individual patient, as Well as the severity of the 
patient’s symptoms. 
In one exemplary application, a suitable amount of com 
pound is administered to a human patient undergoing treat 
ment for cancer. Administration occurs in an amount 
betWeen about 0.1 mg/kg of body Weight to about 20 mg/kg 
of body Weight of a mammal per day, preferably of betWeen 
0.5 mg/kg of body Weight to about 10 mg/kg of body Weight 
of a mammal per day. 
Compounds of the invention may be synthesiZed by 
methods set forth beloW. 
In particular, compounds of formula I may be synthesiZed 
by Scheme 1 or Scheme 2, as appropriate. 
The compounds of formulae III and 11 can be obtained 
via Scheme 1. 
10 
15 
20 
25 
Scheme 1 
W 7 30 \ \ OAc 
1(a) step (a) 
35 O 8 
\ \ \ OAC 
lo) step (b) 
40 R1 IFU\/\)\/\9 R2 N  \ OAc 
45 R3 R5 
R4 
led) 50 step (c,d) 
R1 I'm 10 
R2 N \ \ C1 
55 
R3 R5 
R4 
1(6) \f) 60 
(III) 11 
step (e,f) 
65 Wherein formula R1—R6, III and 11 are as de?ned above. 
Additionally, the compound of formula III may be reacted 
With iodobeads to form the para-iodoaniline compound 
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(reaction step (g), not depicted above). When a compound of 
formula III, Wherein R1, R2, R3, R4, R5, and R6 are H, the 
product of such reaction step (g) is the compound 3 (8-(4 
iodoaniline)-3,7-dimethyl-2,6-octadiene pyrophosphate). 
Reaction Conditions for Scheme 1 
(a) tert-butylhydroperoXide, SeO2, salicylic acid, CH2Cl2; 
(b) the unsubstituted or substituted aniline: 
R1 I|§6 
R2 N\H 
R3 R5 
R4 
Wherein R1—R6 are as indicated in formula III, above, 
NaBH(OAc)3, HOAc, 1,2-dichloroethane; 
(c) K2CO3, MeOH, H2O; 
(d) (Ph)3PCl3, Hunig’s base, CH3CN; 
(f) N-(tert-butoXy carbonyl) cysteine methyl ether; 
(g) iodobeads. 
Compounds of formula III are based on a geranyl skeleton 
Where the terminal isoprene unit of the farnesyl moiety has 
been replaced by an anilino functional group. Species 1 
through 6 above are siX eXamples of molecules that have 
been synthesiZed by the process of Scheme 1. Such com 
pounds possess Widely varied functionality, including para 
iodoanilino, para-nitroanilino, para-aZidoanilino, 
penta?uoroanilino, and para-aZidotetra?uoroanilino groups. 
The methodology for synthesiZing substituted anilino ana 
logs of FPP is robust and versatile. The aniline ring system 
in these analogs provides a platform for the introduction of 
a Wide variety of functional groups and provides a heteroa 
tom linkage connecting the geranyl pyrophosphate moiety to 
the phenyl group Which replaces the terminal isoprene unit. 
The amino linkage is formed by reductive amination of 
the aniline by the geranyl ot-[3 unsaturated aldehyde (8) With 
NaBH(OAc)3 to form the lipid portion of the analog 9. 
Reductive amination of ot-[3 unsaturated aldehydes to 
form anilines has not been previously described in the 
literature. The invention provides for incorporation of 
anilines With very sensitive functional groups such as aryl 
aZides into the analogs. Previously reported methods to form 
this linkage either do not Work or destroy sensitive func 
tional groups. The presence of the amine precluded the 
implementation of standard methods (72—74) to convert the 
lipid allylic alcohol to the desired pyrophosphate via an 
activated chloride intermediate. The present invention uti 
liZes modi?ed published procedures (75) to convert the 
allylic alcohol to the corresponding allylic chloride using 
dichlorotriphenylphosphorane (9%10). The resulting allylic 
chloride Was then converted to the desired pyrophosphate 
analog 1 and the prenyl-analog-cysteine (AG-cys) 11. 
Compounds of formula V, VII and VII may be synthesiZed 
by folloWing Scheme 2. 
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Scheme 2 
HO 
Wk] p = 1-10 
J41) step (a) 
R1 
R2 
0% 15 P c1 
R3 R5 
R4 
law) step (b,c,d) 
R1 
R2 16 
O 
P O 
R3 R5 
R4 
let) step (6.4) 
R1 
R2 M 17 O \ P 0R8 
R3 R5 
R4 
lob) Step (sh) 
R1 
R2 R5 
12 <p=1> 
M (V) 13 EPZZ; O 14 p=3 R3 P \ OPP 
R4 
Wherein RP—R5 are as de?ned above for formula V; and 
suitable choice of p Will yield a compound of formula V, VI 
or VII. 
In formula 17, R8 is an hydroXy protecting group. 
Scheme 2 Reaction Conditions 
(a) benZyl chloride; 
(b) NaOH, ethyl acetoacetate; 
(c) NaOH; 
(d) H2504; 
(e) ethyl diisopropylphosphonoacetate, NaH; 
f) LAH; 
(g) (Ph)3PCl2, Hunig’s base, CH3CN; 
Compounds of formula V are based on an alkyl allylic 
pyrophosphate skeleton Where the middle isoprene unit of 
farnesyl moiety is replaced by a variable length aliphatic 
hydrocarbon chain and the terminal isoprene unit is replaced 
by either an anilino or a benZyl ether function. These 
molecules can adopt a greater range of conformations rela 
tive to the geranyl type analogs because there are feWer 
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unsaturated bonds in the molecules. In addition, the overall 
length of the molecule can be adjusted in single methylene 
increments by changing the length of the hydrocarbon 
linker. Three examples of these molecules With different 
lengths of hydrocarbon linker have been synthesiZed per 
Scheme 2, taking advantage of all the synthetic lessons 
learned in the creation of the ?rst class of analogs. The 
length of the hydrocarbon linker chain is set by the choice 
of benZyl protected uu-chloro-alkanols 15 used to synthesiZe 
the key intermediate ketone 16. This ketone is elaborated to 
the trans-isoprenoid like allylic alcohol 17 by a Horner 
Emmons reaction, folloWed by reduction of the resulting 
ester With lithium aluminum hydride AWide variety 
of benZyl protecting groups (benZyl, p-bromobenZyl, 
p-methoxybenZyl, etc.) are stable to this series of reactions 
and these alcohols can be converted to the corresponding 
pyrophosphates via the chloride. The ?rst example 12 is 
transferred to dansyl peptide by FTase With sloW kinetics, 
shoWing that this class of analogs represents viable struc 
tures for exploring the role of prenyl groups in biological 
systems. 
Compounds of formula VIII can be made by modifying 
the process of Scheme 2 by substituting compounds of the 
general formula HO—CH2—(OCH2CH2)PCl for HOCH2 
(CH2)pCl in the ?rst step of scheme 2. 
Compounds of formula X may be prepared as depicted in 
Scheme 3A. 
Scheme 3A 
Starting Material: 
R1 
R2 MA 0 \ “ 0R8 17 
R3 R5 
R4 
Remove OBZ group HZOAtm) 
j Pd/C 
HOW u 0R8 
Oxidize _ _ 
lSWern Oxidation 
o WW8 
1. K2CO3, MeOH, H20 
2. (Ph)3PCl3, Hunig's base, CH3CN 
3. [(l'kblltyDzNh, HP207, CH3CN 
Reductive amination and pyrophosphorylation to form product X 
R1 
R2 R5 
R3 NVW | . OPP (X) 
R4 R6 
Wherein R1—R6, u, and OPP arc as de?ned above in formula 
X and R8 is an hydroxy protecting group. 
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This pathWay is especially advantageous When the groups 
R1—R5 on the benZyl group are not stable to the LAH 
reduction to produce the alcohol. 
This pathWay may also be used to produce compounds of 
the formula IX by modifying reaction Scheme 3A. The 
suitable starting materials, Which are modi?ed forms of 17 
above, may be produced by the method of Scheme 2, 
Wherein compounds of formula: HOCH2CH2(OCH2CH2) 
tCl (t is 1—5) are substituted for the compound of formula 
HOCH2(CH2)pCl in Scheme 2. The resulting modi?ed ana 
log of 17 is then subjected to the steps outlined in Scheme 
3A to produced IX. 
Compounds of formula VI and VII may be produced by 
the alternate pathWay described in Scheme 3B. 
Scheme 3B 
reduction HZOAtm) 
Pd/C 
HO Mom; 
lOBZ 
Wherein OBZ is optionally substituted by R1—R5 
R4 
R3 R5 
0 \ R2 MOM 
R1 
1. K2CO3, MeOH, H20 
2. (Ph)3PCl3, Hunig's base, CH3CN 
3. [(l'kblltyDzNh, HP207, CH3CN 
pyrophosphorylation 
R4 
R3 R5 
OW R2 q OPP (VI) 
R1 
This pathWay is especially advantageous When the groups 
R1—R5 on the benZyl group are not stable to the LAH 
reduction to produce the alcohol. 
This pathWay may also be used to produce compounds of 
the formula VIII by modifying reaction Scheme 3B. The 
suitable starting materials, Which are modi?ed forms of 17 
above, may be produced by the method of Scheme 2, 
Wherein compounds of formula: HOCH2CH2(OCH2CH2) 
[Cl (t is 1—5) are substituted for the compound of formula 
HOCH2(CH2)pCl in Scheme 2. The resulting modi?ed ana 
log of 17 is then subjected to the steps outlined in Scheme 
3B to produce VIII. 
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The compounds of formula XIII can be obtained from a 
compound of formula VI via the pathway of Scheme 4. 
M 
R4 
R3 R5 
O \ R2 VWOPP v1 
R1 
H2(1 Atm) 
Pd/C 
reduction 
HO VWOH (XIII) 
Wherein R1—R5 are as de?ned in formula VI above; Z is 
1 to 10 and OPP is the pyrophosphate group. 
The corresponding compounds of formula XII may be 
obtained from the compounds of formula VI by removing 
the benZyloXy group via mild hydrogenolysis. 
The compounds of formula XI can be obtained by block 
ing the terminal OH group, converting the 1-hydroXy group 
to the chloride, subjecting the same to pyrophosphorylation 
and ?nally removing the terminal OH group. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
General Methods—[1-3H]farnesyl pyrophosphate FPP, 15 Ci/mmol) and [1-3H]geran geranyl pyrophosphate 
([3H]GGPP, 15 Ci/mmol) Were obtained from American 
Radiochemical Co. Recombinant Wild-type p2lHa'ms pro 
tein (p21H'mS CVLS) and its derivative p21H'mS CVLL Were 
produced in bacteria as described previously (19). 
Geranylgeranyl-cysteine (GG-Cys) and farnesyl-cysteine 
(F-Cys) Were synthesiZed as described by Kamiya et al. (20) 
and puri?ed by preparative TLC. All other solvents and 
chemicals Were reagent grade and purchased from standard 
commercial sources. 
General Synthetic Chemical Procedures. All reactions 
Were conducted under dry argon, and stirred magnetically 
eXcept as noted. Reaction temperatures refer to the eXternal 
bath temperatures. All reactions and ?ash chromatography 
procedures Were conducted under diminished light. Analyti 
cal TLC Was performed on precoated (0.25 mm) silica gel 
60F-254 plates purchased from E. Merck and developed 
With 30% ethyl acetate in hexane, eXcept Where noted 
otherWise. Preparative TLC Was performed on precoated 
silica gel plates Merck #13793-7) purchased from 
Alltech. VisualiZation Was achieved either by UV 
irradiation, anisaldehyde-sulfuric acid spray folloWed by 
heating, or treating the plates With a 5% ethanolic phospho 
molybdic acid solution folloWed by heating. Flash chroma 
tography Was performed on Merck silica gel 60 (230—400 
mesh ASTM) purchased from VWR. All chromatographic 
solvents Were purchased from VWR M. Science— 
OMNISOLV High Purity Grade) and used as received. 
Anhydrous acetonitrile Was purchased from Aldrich. Acti 
vated MnO2 Was purchased from Fluka; all other reagents 
Were either purchased from Aldrich or Alfa Aesar, unless 
otherWise noted. IR spectra Were recorded as liquid ?lms 
using a NICOLET® 560 ESP FTIR spectrometer. NMR 
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spectra Were obtained in CDC13 (unless otherWise noted) at 
200 MHZ With a Varian XL200 spectrometer, or at 500 MHZ 
With a Varian INOVA instrument. Chemical shifts for the 
folloWing deuteriated solvents are reported in ppm doWn 
?eld using the indicated reference peaks: CDCl3 (CDCl3 
internal peak, 7.27 ppm for 1H, 77.4 ppm for 13C), D2O 
(TSP, 0 ppm), CGH6 (CGH6 internal peak, 7.37 ppm for 1H). 
Mass spectra Were obtained With a HeWlett Packard 5890 
Series II gas chromatograph With a 5972 series mass selec 
tive detector. Combustion analyses Were performed by 
Atlantic Microlabs, Inc. Norcross, Ga. 
(E,E)-3,7-Dimethyl-1-acetoXyl-2,6-octadien-8-al (5) 
Geranyl acetate Was oXidiZed as described previously 
With some modi?cation (21). Forty milliliters (0.36 mol) of 
90% tert-butyl hydroperoXide Was added to a stirred sus 
pension of 1.11 g (0.01 mol) of SeO2, 1.4 g (0.01 mol) of 
salicylic acid, and 75 ml of CH2Cl2 in a 250 ml round 
bottom ?ask covered in aluminum foil. The resulting solu 
tion Was alloWed to stir to homogeneity at room temperature 
before being placed at 0° C. After ten minutes, 21.5 ml (0.10 
mol) of geranyl acetate (4) Was introduced dropWise. The 
mixture Was stirred for 5 h at 0° C., and then for 20 h at rt. 
TLC analysis indicated the presence of starting material and 
tWo oXidiZed products (Rf 0.38 aldehyde, Rf 0.19 alcohol). 
The solution Was diluted With 100 ml toluene, and solvents 
Were removed under reduced pressure. The residue Was then 
dissolved in toluene, Washed With 5% NaHCO3 to remove 
H2SeO3, saturated CuSO4, saturated aqueous Na2S2O3 (2><), 
Water, brine, dried over MgSO4 and ?ltered. The solvent Was 
removed under reduced pressure affording a crude oil, Which 
Was dissolved in 100 ml dry CH2Cl2 and cooled to 0° C. 
40.95 g (0.47 mol) of activated MnO2 Was added, and the 
suspension Was stirred for 5 h at 0° C., then overnight at rt. 
The miXture Was ?ltered over a short bed of Celite, and 
Washed thoroughly With dry CH2Cl2. Solvent Was evapo 
rated under reduced pressure to yield a crude, pale yelloW oil 
Which Was puri?ed by ?ash chromatography on silica gel 
(5% EtOAc in heXane) affording 10.68 g (51 %) of 5 as a 
colorless oil; 1H NMR (C6H6, 200 MHZ) 69.47 (s, 1H), 5.98 
(t, 1H, J=6.9 HZ), 5.48 (t, 1H, J=6.9 HZ), 4.75 (d, 2H, J=6.8 
HZ), 2.11 (q, 2H, J=7.3 HZ), 1.92 (t, 2H, J=7.3 HZ), 1.91 (s, 
3H), 1.79 (s, 6H), 1.59 (s, 3H); 13C NMR (50.3 MHZ) 
6195.47, 171.39, 153.70, 140.73, 140.08, 120.01, 61.48, 
38.13, 27.33, 21.37, 16.77, 9.62. 
(E,E) -8 -Aniline -3,7-dimethyl- 1 -acetoXyl-2,6 
octadiene (6) 
The reductive amination procedure of Abdel-Magid et al. 
(22—25) Was modi?ed as folloWs. Into a 250 ml 3-neck ?ask 
covered in aluminum foil Was introduced 150 ml of 1,2 
dichloroethane, folloWed by 7.88 g (37.48 mmol) of 5, 3.76 
ml (41.22 mmol) of fresh aniline, and 2.58 ml (44.89 mmol) 
of glacial acetic acid. After stirring for thirty seconds at 
room temperature, 11.12 g (52.47 mmol) of NaBH(OAc)3 
Was added. The solution Was stirred for 5 h at Which time 
TLC analysis indicated no remaining starting material (Rf of 
6 0.46). The reaction miXture Was quenched by pouring into 
a separatory funnel containing 200 ml of 5% NaHCO3. The 
product Was eXtracted With ether (3><75 ml), dried (MgSO4), 
and concentrated to give a pale yelloW, viscous oil. Puri? 
cation by ?ash chromatography (10% EtOAc in heXane) 
yielded 9.15 g (85%) of a light-straW colored to colorless oil; 
1H NMR (200 MHZ) 67.18 (m, 2H), 6.69 (m, 1H), 6.62 (m, 
2H), 5.38 (m, 2H), 4.60 (d, 2H, J=7.2 HZ), 3.82 (s, 1H), 3.65 
(s, 2H) 2.33—2.02 (m, 4H), 2.08 (s, 3H), 1.72 (s, 3H), 1.69 











